NCT03683433: Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- State
- Under way
- Phase
- Phase 2
- People
- 50 planned
- Started
- 18 Sep 2018
- Primary completion
- 20 Sep 2027
- Arms
- Treatment (azacitidine, enasidenib mesylate)
- Results
- None posted
- 18 Sep 2018: Trial started
- 25 Sep 2018: Trial registered